Inclusion active since November 2020

Enteric hyperoxaluria is a new disease that was not known for five years. Namely, patients in whom there is malabsorption (a state of impaired absorption of nutrients) have paradoxically increased absorption of oxalate minerals in the intestine. Due to the increased absorption and increased excretion of oxalate, the formation of kidney stones can occur. In addition to causing pain, such kidney stones can impair kidney function and cause kidney failure. Numerous diseases can cause malabsorption, for example, chronic inflammation of the pancreas, Crohn’s disease, and larger resections of the small intestine (due to tumors, but also as part of surgical treatment of obesity). There is no standard therapy for this disease. It is in the phase of a clinical trial to be the first drug in history to target oxalate-binding in the gut and prevent oxalate absorption and potentially reduce kidney stone formation. The Solmed Polyclinic is one of the centers in this multinational clinical trial.

Which patients may be potential candidates to participate in the trial?

  • Patients who have been diagnosed with malabsorption due to the aforementioned diseases or have had major bowel surgery at any time in the past, and additionally, have had at least one episode of kidney stones or a proven presence of kidney stones on ultrasound.
  • It is not necessary to have any laboratory findings, they will be made during the initial analysis of the patient, and thus the patient will probably be diagnosed with enteric hyperoxaluria for the first time.